mRNA Technology Transfer: Legal Lessons for Kenya from the Afrigen and WHO Hub Programmes

Kenya BioVax Institute signed its technology transfer agreement with the Medicines Patent Pool on 25 September 2024, and the resulting mRNA manufacturing programme launched publicly in Kenya on 18 February 2026. The technology behind it traces back to Afrigen Biologics in South Africa, the hub at the centre of the World Health Organization’s global mRNA technology transfer programme. A peer-reviewed case study of that South African hub, published after several years of operation, documents specific legal and governance weaknesses in the programme’s structure. Because Kenya’s own agreement follows the same hub-and-spoke, Medicines Patent Pool-intermediated model, those documented weaknesses are worth reading as a checklist before, not after, Kenya’s programme matures.

How the Programme Reached Kenya

WHO announced it was supporting a South African consortium, Afrigen Biologics, the Biovac Institute, and the South African Medical Research Council, to build the first COVID-19 mRNA technology transfer hub on 21 June 2021. Every major high-income-country mRNA originator, including Pfizer, BioNTech, Moderna, and CureVac, declined to share its technology voluntarily, which forced Afrigen to reverse-engineer an mRNA platform from published science rather than receive it directly from an established manufacturer. The Medicines Patent Pool then structured a hub-and-spoke model: Afrigen as the technology-holding hub, and licensing agreements running between the Medicines Patent Pool and a growing list of manufacturing spokes across low- and middle-income countries, Kenya BioVax Institute among them, dated 25 September 2024 on the Medicines Patent Pool’s own published list of agreements. Kenya’s local launch event on 18 February 2026 brought together KEMRI, Kenya BioVax Institute, the Pharmacy and Poisons Board, the Medicines Patent Pool, and technical partners including ThermoFisher, with the stated aim of localizing and optimizing the transferred platform.

What the South African Case Study Found

A case study published in PLOS Global Public Health examined the hub’s first several years and identified structural legal weaknesses worth naming directly. Intellectual property terms were asymmetric: South African university researchers funded through the national medical research council could earn royalties on resulting inventions, while the low- and middle-income-country manufacturing spokes were required to license the technology royalty-free, an inversion that one programme official described as disconnected from the initiative’s affordability goals. Freedom-to-operate protection was weaker than promised: the Medicines Patent Pool’s own agreements commit only to providing intellectual property analysis “as practicable” rather than a genuine freedom-to-operate opinion, and Afrigen ultimately had to commission independent legal advice at its own expense because a summary patent database search is not an adequate substitute. Governance was centralized in Geneva, with funding and decision-making concentrated in Medicines Patent Pool committees that excluded recipient-country government representatives entirely, and technology transfer relationships ran through the Medicines Patent Pool as intermediary rather than directly between Afrigen and each spoke, which one partner said introduced avoidable bureaucratic distance and risked losing tacit knowledge in the handoff. Finally, pricing and affordability commitments applied only to products addressing a WHO-declared public health emergency, leaving ordinary commercial products to market competition alone.

What Kenya’s Own Agreement Inherits

Kenya BioVax’s position as a spoke under the same Medicines Patent Pool-brokered structure means the same contractual architecture criticized in the South African case study applies here by default unless Kenya negotiated variations. That is a legal due diligence question worth asking directly of Kenya BioVax and KEMRI rather than assuming it has already been resolved: does Kenya’s technology transfer agreement carry the same royalty-free spoke obligation paired with a royalty-bearing arrangement upstream, does it rely on the same “as practicable” intellectual property analysis language, and does it route the working relationship through the Medicines Patent Pool rather than giving Kenya BioVax a direct technical line to Afrigen. None of this is publicly disclosed at the level of detail needed to answer definitively, which is itself a governance point the case study raises: agreements negotiated without public disclosure of terms are harder for a recipient country’s own stakeholders, including its Parliament and civil society, to scrutinize.

A Domestic Legal Backstop That Has Not Been Tested Here

Kenya’s Industrial Property Act, No. 3 of 2001, gives the country its own compulsory licensing tools independent of whatever the Medicines Patent Pool’s agreements provide. Sections 72 to 75 allow compulsory licences for non-working of a patented invention in Kenya and for patents that are interdependent, subject to preconditions and terms set by the Industrial Property Tribunal. Section 80 separately allows the government, or a third party it authorises, to exploit a patented invention without the patent owner’s consent under specified circumstances. Neither provision has been tested in the context of mRNA technology transfer, and neither should be assumed to be a fast or simple remedy if a freedom-to-operate gap later surfaces in a patent Afrigen’s own legal advice did not catch. The more useful lesson from the South African experience is upstream: Kenya should treat independent Kenyan patent counsel, engaged before manufacturing scales up, as a cost of doing the deal properly, not an optional extra once a dispute has already emerged.